Metabasis' liver-cancer treatment well tolerated in first dose-escalation trial

By Elaine Rigoli

Tampa, Fla., June 5 - Metabasis Therapeutics, Inc. said Monday that the results of the first dose escalation trial show that MB07133 at doses up to 2,400 mg/m2/day IV infusion is well tolerated in patients with unresectable hepatocellular carcinoma and that there were no clinically significant dose-limiting toxicities associated with the therapy.

MB07133 is a novel drug candidate that uses the company's HepDirect technology to target production of an activated form of cytarabine to the liver.

A pharmacokinetic analysis was conducted and the results are consistent with MB07133's expected liver-targeting mechanism, according to a news release.

Although this study was not designed to demonstrate the efficacy of the candidate, encouraging signs of drug activity were observed, including evidence of tumor shrinkage and disease stabilization.

Metabasis is a biopharmaceutical company with headquarters in La Jolla, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.